SHORT MINI FUTURE WARRANT - BRISTOL-MYERS SQUIBB | Real-time BOERSE MUENCHEN 04:25:56 2024-07-03 EDT | ||
| 5.066 EUR | +0.06% |
|
| Current month | +2.43% | ||
| 1 month | +2.01% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-07-03 | 5.066 | +0.06% |
| 24-07-02 | 5.063 | +1.30% |
| 24-07-01 | 4.998 | +1.11% |
| 24-06-28 | 4.943 | -0.74% |
| 24-06-27 | 4.98 | +1.67% |
Real-time BOERSE MUENCHEN
Last update July 03, 2024 at 04:25 am
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | Goldman Sachs |
| WKN | GZ4MP3 |
| ISIN | DE000GZ4MP36 |
| Date issued | 2022-12-02 |
| Strike | 94.93 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.53 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.085 € |
|---|---|
| Lowest since issue | 1.509 € |
| Spread | 0.01 € |
| Spread % | 0.20% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
40.45
USD
Average target price
53.19
USD
Spread / Average Target
+31.51%
- Stock Market
- Certificates
- Certificat
